Literature DB >> 8572660

Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen.

U Malik1, L Oleksowicz, N Latov, L J Cardo.   

Abstract

In this study, we preincubated the sera of 3 patients with neuropathies associated with elevated titers of IgM anti-GM1 antibodies, with increasing concentrations of intravenous Ig (IVIg) and assayed the inhibitory effect of this mixture on antibody binding to immobilized GM1 by an enzyme-linked immunosorbent assay. Pharmacologic concentrations of IVIg, ranging from 0.1 microgram/ml to 100 mg/ml, inhibited anti-GM1 binding to its target antigen from 26 +/- 3 to 71 +/- 7%, respectively, in a dose-dependent manner. A similar inhibition of binding was also observed with IVIg F(ab')2 fragments. These findings provide a possible mechanism for the clinical efficacy of IVIg in motor neuropathies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8572660     DOI: 10.1002/ana.410390121

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  10 in total

1.  Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils.

Authors:  Ian K Campbell; Sylvia Miescher; Donald R Branch; Patrick J Mott; Alan H Lazarus; Dongji Han; Eugene Maraskovsky; Adrian W Zuercher; Anton Neschadim; Danila Leontyev; Brent S McKenzie; Fabian Käsermann
Journal:  J Immunol       Date:  2014-04-23       Impact factor: 5.422

Review 2.  Multifocal motor neuropathy: current therapies and novel strategies.

Authors:  Eduardo Nobile-Orazio; Francesca Gallia
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

3.  rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcγRs.

Authors:  Rolf Spirig; Ian K Campbell; Sandra Koernig; Chao-Guang Chen; Bonnie J B Lewis; Rebecca Butcher; Ineke Muir; Shirley Taylor; Jenny Chia; David Leong; Jason Simmonds; Pierre Scotney; Peter Schmidt; Louis Fabri; Andreas Hofmann; Monika Jordi; Martin O Spycher; Susann Cattepoel; Jennifer Brasseit; Con Panousis; Tony Rowe; Donald R Branch; Adriana Baz Morelli; Fabian Käsermann; Adrian W Zuercher
Journal:  J Immunol       Date:  2018-03-12       Impact factor: 5.422

4.  Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.

Authors:  Saiju Jacob; Yusuf A Rajabally
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

Review 5.  Mechanistic effects of IVIg in neuroinflammatory diseases: conclusions based on clinicopathologic correlations.

Authors:  Marinos C Dalakas
Journal:  J Clin Immunol       Date:  2014-04-11       Impact factor: 8.317

Review 6.  Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies.

Authors:  Melvin Berger; Daniel E McCallus; Cindy Shin-Yi Lin
Journal:  J Peripher Nerv Syst       Date:  2013-12       Impact factor: 3.494

Review 7.  Human immune globulin infusion in the management of multifocal motor neuropathy.

Authors:  Elizabeth Jovanovich; Chafic Karam
Journal:  Degener Neurol Neuromuscul Dis       Date:  2015-12-22

Review 8.  IgG4-Mediated Neurologic Autoimmunities: Understanding the Pathogenicity of IgG4, Ineffectiveness of IVIg, and Long-Lasting Benefits of Anti-B Cell Therapies.

Authors:  Marinos C Dalakas
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-11-29

Review 9.  Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy.

Authors:  Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2021-11-11       Impact factor: 7.620

Review 10.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.